Form 8-K - Current report:
SEC Accession No. 0001213900-24-064993
Filing Date
2024-08-05
Accepted
2024-08-05 07:30:34
Documents
15
Period of Report
2024-08-05
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0210560-8k_actinium.htm   iXBRL 8-K 25885
2 PRESS RELEASE, DATED AUGUST 5, 2024 ea021056001ex99-1_actinium.htm EX-99.1 20793
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10806
  Complete submission text file 0001213900-24-064993.txt   242458

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE atnm-20240805.xsd EX-101.SCH 3033
5 XBRL LABEL FILE atnm-20240805_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE atnm-20240805_pre.xml EX-101.PRE 22371
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0210560-8k_actinium_htm.xml XML 3688
Mailing Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017
Business Address 100 PARK AVE., 23RD FLOOR NEW YORK NY 10017 (646) 677-3870
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 241173101
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)